Research Research Areas Research Groups Selected Publications Selected Projects Open Science
Laboratories Core Facilities Booking system RICAIP Testbed Brno Industry Cooperation
Education PhD School Postdoc Programme Seminar Series Summer School Internships Secondary Teachers
Career Training Jobs MSCA–PF HRS4R Award Alumni Network Welcome Office Innovation Accelerator
About Us News Events People Organisational Structure Scientific Evaluation To Download Press and Media Contacts
CZ
Home Research Selected Publications BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response
Share Share Share

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response

LEUKEMIA & LYMPHOMA

Simara, P; Peterkova, M; Stejskal, S; Potesilova, M; Koutna, I; Racil, Z; Razga, F; Jurcek, T; Dvorakova, D; Mayer, J, 2012: BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. LEUKEMIA & LYMPHOMA 53(8), p. 1627 - 1629, doi: 10.3109/10428194.2012.656104

CEITEC authors: